Evidence map›Paper›PMID 41757049›Full record

ArticlebioRxiv : the preprint server for biology2026

Acid sphingomyelinase inhibition restores RPE homeostasis and photoreceptor function in preclinical Stargardt macular degeneration models.

Colin J Germer, Sydney Williams, Valencia Fernandes, Ricardo Espinosa Lima, Nilsa R La Cunza, Li Xuan Tan, Samir Ranjan Panda, Emma Iorio, Fanny M Elahi, Aparna Lakkaraju

Abstract readPreprint
PubMed Full text at PMC Publisher
In one paragraph

Article in bioRxiv : the preprint server for biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Colin J GermerDepartment of Ophthalmology, School of Medicine, University of California, San Francisco, CA, USA.
Sydney WilliamsDepartment of Ophthalmology, School of Medicine, University of California, San Francisco, CA, USA.
Valencia FernandesDepartment of Ophthalmology, School of Medicine, University of California, San Francisco, CA, USA.
Ricardo Espinosa LimaDepartment of Ophthalmology, School of Medicine, University of California, San Francisco, CA, USA.
Nilsa R La CunzaDepartment of Ophthalmology, School of Medicine, University of California, San Francisco, CA, USA.
Li Xuan TanDepartment of Ophthalmology, School of Medicine, University of California, San Francisco, CA, USA.
Samir Ranjan PandaDepartment of Ophthalmology, School of Medicine, University of California, San Francisco, CA, USA.
Emma IorioDepartment of Neurological Surgery, University of California, San Francisco, CA, USA.
Fanny M ElahiDepartment of Neurology, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Aparna LakkarajuDepartment of Ophthalmology, School of Medicine, University of California, San Francisco, CA, USA.

Funding

Rapid-Prototyping and Design CoreP30EY002162 · NEI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI ULLIAN, ERIK M · 1985 to 2024
$16.8M
UW Vision Research Core - Administrative CoreP30EY016665 · NEI · UNIVERSITY OF WISCONSIN-MADISON · PI AKIHIRO IKEDA · 2005 to 2026
$12.6M
Mechanisms of RPE dysfunction in macular degenerations: role of intracellular complement activationR01EY030668 · NEI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI LAKKARAJU, APARNA · 2020 to 2024
$3.5M
Mechanisms of cellular clearance in the retinal pigment epitheliumR01EY023299 · NEI · UNIVERSITY OF WISCONSIN-MADISON · PI LAKKARAJU, APARNA · 2015 to 2019
$2.3M
Vision Bioinformatics and ComputationP30EY037668 · NEI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Erik M Ullian · 2025 to 2026
$2.0M
Triple threat therapeutics for inherited retinal degenerationsR01EY035514 · NEI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Aparna Lakkaraju · 2024 to 2026
$1.6M
NEI NIH HHS P30 EY002162NEI NIH HHS P30 EY016665NEI NIH HHS P30 EY037668NEI NIH HHS R01 EY023299NEI NIH HHS R01 EY030668NEI NIH HHS R01 EY035514
6 · The paper itself

Abstract

Stargardt disease, which destroys central high-resolution vision in over 2 million people globally, lacks effective therapies. The primary site of damage in Stargardt disease is the retinal pigment epithelium (RPE), which safeguards photoreceptor health and function. Progressive loss of RPE integrity precedes visual deficits, yet insight into mechanisms driving RPE dysfunction and how this influences disease pathogenesis remains elusive. Here, we addressed this in cell-based and pigmented

Identifiers

PMID41757049
PMCPMC12934583

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.